Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson caught up with Proactive's Andrew Scott soon after reporting that early results from its first-in-human study of its proprietary DurAVR™ aortic valve found that patient outcomes exceeded the results of what is normally expected following a Surgical Aortic Valve Replacement (SAVR). The DurAVR™ valve was easy to manipulate and was able to be optimally positioned by the implanting surgeon in the aortic valve replacement procedures, promoting better results.
Anteris Technologies CEO hails 'very good results' from DurAVR™ human study
Quick facts: Anteris Technologies Ltd
Price: 3.94 AUD
Market Cap: $23.29 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE